Heidelberg Pharma (HPHA) Q3 2025 earnings summary

Executive summary

• Lead ADC candidate HDP-101 advanced to ninth cohort in Phase I/IIa trial, showing strong safety and efficacy signals in relapsed/refractory multiple myeloma patients.

• Strategic refocus on HDP-101 due to delayed milestone payment; 75% workforce reduction and pausing of other programs.

• New clinical data for HDP-101 presented at IMS Annual Meeting, with several patients achieving partial or very good partial responses.

Financial highlights

• Sales revenue for 9M 2025 was EUR 1.4 million, down from EUR 5.2 million year-over-year.

• Other income rose to EUR 5.0 million (prior year: EUR 2.4 million), mainly from exchange rate gains.

• Operating expenses increased to EUR 28.2 million (prior year: EUR 22.8 million), driven by higher R&D costs for HDP-101.

• Net loss widened to EUR 21.1 million from EUR 14.3 million year-over-year; EPS at EUR -0.45 (prior year: EUR -0.31).

• Cash at period end was EUR 22.9 million, down from EUR 36.6 million a year earlier.

Outlook and guidance

• 2025 sales and other income expected between EUR 7.5–9 million (previously EUR 9–11 million).

• Operating expenses forecasted at EUR 36–40 million (previously EUR 40–45 million).

• EBIT expected between EUR -28.5 million and EUR -31 million.

• Cash requirements for 2025 estimated at EUR 14–17 million; financing secured until mid-2026.